Holen Sie sich die Stockscreener-App
145.76
1.56%
2.24
Schlusskurs vom Vortag:
$143.52
Offen:
$144.64
24-Stunden-Volumen:
2.86M
Relative Volume:
2.15
Marktkapitalisierung:
$10.10B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$302.80M
KGV:
33.93
EPS:
4.2965
Netto-Cashflow:
$387.80M
1W Leistung:
-2.30%
1M Leistung:
-4.41%
6M Leistung:
-50.23%
1J Leistung:
-51.70%
1-Tages-Spanne:
$142.10
$146.22
1-Wochen-Bereich:
$142.10
$150.89
52-Wochen-Spanne:
$140.63
$354.88
Insulet Corp Stock (PODD) Company Profile
Firmenname
Insulet Corp
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
145.76 | 10.10B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corp Aktie (PODD) Neueste Nachrichten
Insulet (PODD) Announces Positive Clinical Trial Results for Next-Generation Omnipod 6 AID System - Insider Monkey
Insulet StockFriday sector check and weekly review - AD HOC NEWS
Insulet Corporation Stock: Is PODD Underperforming the Healthcare Sector? - Yahoo Finance
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Corporation Stock (PODD) Opinions on Diabetes Technology Developments - Quiver Quantitative
Insulet Corp (PODD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insulet Corp (PODD) Institutional Confidence - TradingKey
Insulet Corp (PODD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insulet Corp (PODD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Insulet Corp (PODD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Insulet Corp (PODD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Insulet Corp (PODD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corp (PODD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Federal Circuit Holds That DTSA Statute of Limitations Starts Running When Plaintiff Has Enough Facts to PleadNot Necessarily to ‘Prove’a DTSA Claim - JD Supra
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet Stock (US45784P1012): Ownership Changes Put Diabetes Tech Group in Focus - AD HOC NEWS
Top medtech stories from ADA’s Scientific Sessions - MedTech Dive
Why is Insulet (PODD) down 8.7% since last earnings report? - MSN
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Is Insulet Corporation (PODD) A Good Stock To Buy Now? - Yahoo Finance
Truist cuts Insulet stock price target to $219 on valuation - Investing.com
Assessing Insulet (PODD) Valuation After New Omnipod Clinical Data And System Updates - Yahoo Finance
Insulet Corporation $PODD Shares Sold by Allianz Asset Management GmbH - MarketBeat
Insulet Corp (PODD) Shares Surge 5.3% -- What GF Score of 82 Tel - GuruFocus
Insulet: When the Time Runs Out on Undiscovered Trade Secret Claims - Steptoe
Insulet Independent Chair Acquires 66% More Stock - Moomoo
Insulet reports new data for Omnipod 6 and FCL systems - MSN
Insulet (PODD) Enhances Omnipod 5 System with New Target Glucose Option - Insider Monkey
Insulet (PODD) Reveals Promising Advances in Automated Insulin D - GuruFocus
Prudential PLC Has $5.68 Million Stock Position in Insulet Corporation $PODD - MarketBeat
CIBC Asset Management Inc Purchases 6,821 Shares of Insulet Corporation $PODD - MarketBeat
5 Oversold Stocks to Buy Right Now - Insider Monkey
ETFs Investing in Insulet Corporation Stocks - TradingView
Soleus Capital Management, L.P.'s Insulet Corp(PODD) Holding History - GuruFocus
INSULET CORP (NASDAQ:PODD) Fits the Affordable Growth Mold with Strong Momentum and Reasonable Valuation - ChartMill
Insulet presents clinical trial data for diabetes devices - Investing.com
Insulin pump trials: Omnipod 6 lifts time in range with fewer boluses - Stock Titan
Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care - Yahoo Finance
Earnings call transcript: Insulet’s Q1 2026 earnings beat expectations, stock dips - Investing.com
Insulet shares surge 9% on strong earnings beat - Investing.com
Federal Circuit Overturns $59 Million Trade Secret Award Against EOFlow In Statute Of Limitations Ruling - londoninsider.co.uk
Insulet shares rise as investors focus on Omnipod 5 software upgrade and expanded CGM compatibility - Quiver Quantitative
Moody’s revises Insulet outlook on product recall concerns - Investing.com
PODD Stock Balances Device Setback With Omnipod Upgrade Momentum - StocksToTrade
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report? - Yahoo Finance
Divided Federal Circuit Panel Nixes $452 Million Trade Secret Judgment as Time-Barred - Holland & Knight
Dexcom buys Nutrisense; Insulet rolls out patch pump update - Yahoo Finance
Is Omnipod 5’s Algorithm and Libre 3 Plus Upgrade Altering The Investment Case For Insulet (PODD)? - Yahoo Finance
Insulet Q1 2026 slides: 34% revenue growth amid stock decline - Investing.com
Insider Buying: Timothy Stonesifer Acquires Shares of Insulet Co - GuruFocus
Finanzdaten der Insulet Corp-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):